Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACTH4-10Pro8-Gly9-Pro10 is a synthetic peptide analogue derived from the adrenocorticotropic hormone (ACTH), specifically corresponding to amino acids 4 through 10 with substitutions at positions 8 (proline), 9 (glycine), and 10 (proline). It is devoid of classical hormonal effects but exhibits neuromodulatory and neuroprotective properties. The drug has demonstrated anti-inflammatory effects by reducing pro-inflammatory cytokines such as IL-6 and IL-8, while increasing anti-apoptotic proteins like Bcl-2 and neurotrophic factors such as BDNF. These actions are associated with reduced neuronal apoptosis, enhanced neuronal survival, improved recovery in models of traumatic brain injury, spinal cord injury, stroke, and Alzheimer’s disease. The compound can be administered intranasally for rapid onset[2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acth4-10pro8-gly9-pro10.